麻豆女优

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • 麻豆女优 Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

TRENDING TOPICS:

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Oct 9 2015

Full Issue

Biotech Stock Poised For Big Gain Or Big Fall

One Wall Street analyst says there's no middle ground forward for investment in biotech firms, whose products are becoming the focus of scrutiny after big price hikes. Elsewhere, a new multiple sclerosis drug from Roche shows promise, and there's news on a takeover bid by Blackstone and an impending sale by Clayton, Dubilier & Rice of a drug-compounding firm.

Biotechnology stocks can鈥檛 catch a break. And one Wall Street strategist says the volatile price action recently has him expecting one of two things: A sharp turnaround or a deeper plunge. 鈥淭he group isn鈥檛 a 鈥楤uy鈥 or 鈥楽ell鈥 here 鈥 it is either 鈥楽trong Buy鈥 or 鈥楽trong Sell,鈥欌 wrote Nicholas Colas, chief market strategist at brokerage Convergex. Biotechs have long been a volatile sector, well outperforming the large-cap S&P index during good times and significantly underperforming during bad times. (Scholer, 10/8)

Roche Holding AG鈥檚 Genentech unit said its experimental drug ocrelizumab proved effective in three late-stage studies against multiple sclerosis, potentially heralding an important new treatment option for the debilitating disease. In two of the studies, which included 1,656 patients with relapsing multiple sclerosis, the most common form of the condition, ocrelizumab proved superior to the commonly used drug, Rebif, in reducing the annual rate of relapse of major symptoms and other measures of the status of the disease, Roche said. (Winslow, 10/8)

Blackstone Group agreed to buy landlord BioMed Realty Trust Inc. for $4.8 billion, betting on growth in real estate demand from the life sciences and biotechnology industries. Shares of REITs have been battered this year as investors gird for the first interest-rate hike since 2006, creating opportunities for buyers like New York-based Blackstone to acquire companies relatively cheaply. Health-care spending is rising quickly in the United States, boosting demand for laboratory space that can accommodate pharmaceutical developers and manufacturers. (Callanan and Mulholland, 10/8)

Clayton Dubilier & Rice鈥檚 planned sale of drug-compounding company PharMEDium Healthcare Holdings Inc. for $2.58 billion stands to land the private equity firm a nice return on its investment. It also reflects revived interest in compounding pharmacies, which mix or dilute pharmaceutical agents to create hospital-grade dosage forms that aren鈥檛 commercially available. (Or, 10/8)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
  • Monday, April 20
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 麻豆女优